Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Lel H who wrote (118)	7/12/1998 10:40:00 AM
From: Timothy Kross	Read Replies (2) \| Respond to of 626

To: Lel From: Tim The information that I posted came from the 1997 annual report which states that Titan Pharmaceuticals retains full rights to the Japanese market. Also on page 34 of the report it states that Novartis sublicense agreement for Iloperidone excludes Japan. Your conclusions make sense when one considers that Japan has roughly half the population of the United States and that Titan will receive 100% of the profits from the sale of iloperidone in that country. Whereas, in this country and the rest of the world, Titan is receiving only a percentage royalty on the net sales.